Literature DB >> 34938544

Traumatic epidural hematoma in a patient with severe schizencephaly.

Van Trung Hoang1, The Huan Hoang1, Vichit Chansomphou2, Dung Tien Doan3.   

Abstract

Schizencephaly is a rare congenital brain structural abnormality that is not clearly understood and has no specific treatment yet. Therefore, cases related to it should be added to the literature. This report aims to introduce a rare case of severe schizencephaly co-occurring with post-traumatic intracranial epidural hematoma.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  central nervous system malformation; computed tomography; epidural hematoma; extradural hematoma; schizencephaly

Year:  2021        PMID: 34938544      PMCID: PMC8665687          DOI: 10.1002/ccr3.5150

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


INTRODUCTION

Schizencephaly is known as a split‐brain disorder that is a rare congenital developmental malformation of the central nervous system. It is characterized by clefts in the cerebral tissue that are commonly located in the Sylvian region and can be unilateral or bilateral. They connect the pial surface to the ependymal surface of the ventricle through the white matter to the pial surface and are usually covered by gray matter with infrequent focal microgyria. We report a 5‐year‐old boy who has an incidental diagnosis of schizencephaly after traumatic brain injury.

CASE PRESENTATION

A 5‐year‐old boy was admitted to the hospital in a state of traumatic brain injury due to a fall and hit his right parietal head against the wall. His history was presented with motor and mental retardation accompanied by occasional seizures. Family history was unremarkable. Vital signs including pulse, temperature, blood pressure, and respiratory rate were all normal limits. Laboratory evaluations were nothing unremarkable. Physical examination revealed mild scalp swelling in the right parietal region. The patient presented with a headache with delayed mental and motor response. He underwent a computed tomography (CT) scan of the head, which showed skull fracture with epidural hematoma in the right parietal region (Figure 1). Furthermore, there were severe brain defects with bilateral wide clefts and absence of septum pellucidum and corpus callosum (Figure 2). Due to the motion artifacts, magnetic resonance imaging technique was not performed despite the best efforts. The patient received only conservative treatment and was discharged from the hospital later. The boy was followed up showing remission of the hematoma after 2 weeks. However, the growth retardation remained unchanged as no cure for the problem was found.
FIGURE 1

Axial, coronal, and sagittal CT images show skull bone fracture (red circle) and epidural hematoma (yellow arrows) in the right parietal region

FIGURE 2

CT images show large brain defects in most of the bilateral frontal, parietal, and temporal lobes communicating with the ventricles by wide clefts (red dotted lines). The septum pellucidum and corpus callosum are absent. Note that MRI is more sensitive than CT for detecting gray matter abnormalities

Axial, coronal, and sagittal CT images show skull bone fracture (red circle) and epidural hematoma (yellow arrows) in the right parietal region CT images show large brain defects in most of the bilateral frontal, parietal, and temporal lobes communicating with the ventricles by wide clefts (red dotted lines). The septum pellucidum and corpus callosum are absent. Note that MRI is more sensitive than CT for detecting gray matter abnormalities

DISCUSSION

Schizencephaly was first described by Wilmarth in 1887, then Yakovlev and Wadsworth proposed a two‐type classification (closed‐lip type: not communicating with the ventricular system; open‐lip type: communicating with the ventricular system) in 1946, and Griffiths proposed a three‐type classification (type 1: trans‐mantle column of abnormal gray matter but no evidence of a CSF‐containing cleft; type 2: CSF‐containing cleft present, abutting lining lips of abnormal gray matter opposed; type 3: CSF‐containing cleft present, non‐abutting lining lips of abnormal gray matter) in 2018. Most cases of schizencephaly are non‐familial and sporadic. The frequency is about 1.5 per 1,000,000 live births, and the frequency of epilepsy is 1 per 1650. , There is no clear gender distinction but males are slightly more dominant. The etiology is not well understood but those that cause destruction of brain tissue (eg, vascular insult; ischemia; stroke; autoimmune vasculitis; infections caused by TORCH syndrome, toxoplasmosis, syphilis, varicella‐zoster, parvovirus B19, rubella, cytomegalovirus, herpes; early prenatal injuries related to drug abuse or abdominal trauma of the mother; the frequent coincidence of other central nervous system malformations such as polymicrogyria and gray matter heterotopia; factors of inhibiting brain development); and disorders of nerve cell migration (eg, disturbed migration of primitive neuroblasts; mutations of Lhx2 or EMX2 gene) lead to schizencephaly. , Clinical severity depends on defect type, cleft size, cleft location, unilateral versus bilateral defect, the extent of the cerebral tissue damage, and the extent of anatomic abnormalities of other neural structures involved. Clinical manifestations of schizencephaly are variable and heterogeneous, such as neuro‐psychologic disorder, neurobehavioral abnormality, motor impairment, psychomotor developmental delay, intellectual dysfunction, language behavior disorder, seizure, epilepsy, microcephaly, muscle hypotonia, focal neurologic signs, spastic diparesis, hemiplegia, etc. , , Image methods give a demonstration of anatomic changes as well as in identifying other associated lesions. They delineate gray matter lining the defect and the communication with the ventricle. MRI is more sensitive than CT in detecting the clefts as well as additional abnormalities such as polymicrogyria, pachygyria, heterotopic gray matter, optic nerve hypoplasia, septo‐optic dysplasia, agenesis of the septum pellucidum and corpus callosum, etc. , Differential diagnosis of schizencephaly includes gray matter abnormalities (focal cortical dysplasia, polymicrogyria‐pachygyria, and band of heterotopic gray matter) and CSF‐containing defects (arachnoid cyst, porencephaly, ventriculomegaly, monoventricle in holoprosencephaly, hydranencephaly, hydrocephalus, agenesis of the corpus callosum with an interhemispheric cyst). Currently, there are no specific therapeutic options for schizencephaly yet. Conservative treatment is applicable in most cases. Surgical implantation of a shunt system is only applied in cases of acute life‐threatening intracranial hypertension. , , Accurate detection and diagnosis can assist in the follow‐up of schizencephaly. Gene and stem cell therapy needs more research. Head trauma in patients with schizencephaly may be more severe than in normal patients because of poor behavioral control. Care of epidural hematoma in patients with schizencephaly should be with an interdisciplinary approach. An interprofessional team is established in this situation including a pediatrician, psychiatrist, neurologist, neurosurgeon, nurse, and pharmacist. In these patients, conservative management should be attempted; surgical treatment is only performed in case the epidural hematoma causing severe symptoms. , , ,

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

VTH involved in writing and conceptualization. THH involved in data curation and diagnosis confirmation. VC and DTD involved in review and revision. All authors read and approved the final manuscript.

ETHICAL APPROVAL

Ethics approval was not required for this study.

CONSENT

Written informed consent was obtained for use of the clinical images.
  9 in total

Review 1.  Schizencephaly: A Review of 734 Patients.

Authors:  Vinícius Lopes Braga; Marcos Devanir Silva da Costa; Rachel Riera; Luana Pompeu Dos Santos Rocha; Bruno Fernandes de Oliveira Santos; Thiago Toshiyuki Matsumura Hondo; Michelle de Oliveira Chagas; Sergio Cavalheiro
Journal:  Pediatr Neurol       Date:  2018-08-08       Impact factor: 3.372

2.  Schizencephalies; a study of the congenital clefts in the cerebral mantle; clefts with fused lips.

Authors:  P I YAKOVLEV; R C WADSWORTH
Journal:  J Neuropathol Exp Neurol       Date:  1946-04       Impact factor: 3.685

Review 3.  Fetal schizencephaly: pre- and postnatal imaging with a review of the clinical manifestations.

Authors:  Karen Y Oh; Anne M Kennedy; Antonio E Frias; Janice L B Byrne
Journal:  Radiographics       Date:  2005 May-Jun       Impact factor: 5.333

4.  Clinical and radiologic features of unilateral and bilateral schizencephaly in polish pediatric patients.

Authors:  Ilona Kopyta; Ewa Jamroz; Ewa Kluczewska; Beata Sarecka-Hujar
Journal:  J Child Neurol       Date:  2013-03-14       Impact factor: 1.987

5.  Schizencephaly: association with young maternal age, alcohol use, and lack of prenatal care.

Authors:  Kira A Dies; Adria Bodell; Fuki M Hisama; Chao-Yu Guo; Brenda Barry; Bernard S Chang; A James Barkovich; Christopher A Walsh
Journal:  J Child Neurol       Date:  2012-12-23       Impact factor: 1.987

6.  Schizencephaly-diagnostics and clinical dilemmas.

Authors:  Agata Halabuda; Lukasz Klasa; Stanislaw Kwiatkowski; Lukasz Wyrobek; Olga Milczarek; Aleksandra Gergont
Journal:  Childs Nerv Syst       Date:  2015-02-18       Impact factor: 1.475

7.  Diagnostic imaging and problems of schizencephaly.

Authors:  Joanna Stopa; Iwona Kucharska-Miąsik; Ewa Dziurzyńska-Białek; Agnieszka Kostkiewicz; Anna Solińska; Monika Zając-Mnich; Wiesław Guz; Antoni Samojedny
Journal:  Pol J Radiol       Date:  2014-11-30

8.  A rare case of schizencephaly in an adult with late presentation.

Authors:  Vijaya Kamble; Amol Madanlal Lahoti; Avinash Dhok; Abhijeet Taori; Nilufer Pajnigara
Journal:  J Family Med Prim Care       Date:  2017 Apr-Jun

9.  Schizencephaly revisited.

Authors:  Paul D Griffiths
Journal:  Neuroradiology       Date:  2018-07-19       Impact factor: 2.804

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.